Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Advancing Access to Precision Medicine Act
Client: MYRIAD GENETIC LABORATORIES, INC. · Firm: MYRIAD GENETIC LABORATORIES, INC.
Section 216(a) of the Protecting Access to Medicare Act of 2014 (PAMA) (Pub. L. 113- 93) - payment and coding for laboratory tests Billing rules for laboratory tests; date of service rule/14 day rule National Coverage Decision on next generation sequencing tests HR 5062 - Advancing Access to Precision Medicine Act
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
MYRIAD GENETIC LABORATORIES, INC. via MYRIAD GENETIC LABORATORIES, INC.
2018 · second_quarter · Q2
Regulation of laboratory developed tests - discussion draft (no HR #) Diagnostic Accuracy and Innovation Act (DAIA)
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
MYRIAD GENETIC LABORATORIES, INC. via MYRIAD GENETIC LABORATORIES, INC.
2018 · first_quarter · Q1
Source: Senate LDA
Section 216(a) of the Protecting Access to Medicare Act of 2014 (PAMA) (Pub. L. 113- 93) - payment and coding for laboratory tests Billing rules for laboratory tests; date of service rule/14 day rule National Coverage Decision on next generation sequencing tests HR 5062 - Advancing Access to Precision Medicine Act
Regulation of laboratory developed tests - discussion draft (no HR #) Diagnostic Accuracy and Innovation Act (DAIA)
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
MYRIAD GENETIC LABORATORIES, INC. via MYRIAD GENETIC LABORATORIES, INC.
2017 · fourth_quarter · Q4
Section 216(a) of the Protecting Access to Medicare Act of 2014 (PAMA) (Pub. L. 113- 93) - payment and coding for laboratory tests Billing rules for laboratory tests; date of service rule/14 day rule CLFS CY2018 Preliminary Determinations National Coverage Decision on next generation sequencing tests
Regulation of laboratory developed tests - discussion draft (no HR #) Diagnostic Accuracy and Innovation Act (DAIA)
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
MYRIAD GENETIC LABORATORIES, INC. via MYRIAD GENETIC LABORATORIES, INC.
2017 · third_quarter · 3A
Patent eligibility
Regulation of laboratory developed tests - discussion draft (no HR #) Diagnostic Accuracy and Innovation Act (DAIA)
Section 216(a) of the Protecting Access to Medicare Act of 2014 (PAMA) (Pub. L. 113- 93) - payment and coding for laboratory tests Billing rules for laboratory tests; date of service rule/14 day rule CLFS CY2018 Preliminary Determinations
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
MYRIAD GENETIC LABORATORIES, INC. via MYRIAD GENETIC LABORATORIES, INC.
2017 · third_quarter · Q3
Patent eligibility
Regulation of laboratory developed tests - discussion draft (no HR #) Diagnostic Accuracy and Innovation Act (DAIA)
Section 216(a) of the Protecting Access to Medicare Act of 2014 (PAMA) (Pub. L. 113- 93) - payment and coding for laboratory tests Billing rules for laboratory tests; date of service rule/14 day rule CLFS CY2018 Preliminary Determinations
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE